Found 285 clinical trials
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)
- 106 views
- 08 Nov, 2020
- 1 location
A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)
A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)
- 84 views
- 25 Mar, 2021
- 1 location
A Phase 3 Randomized, Double-blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
- 130 views
- 25 Mar, 2021
- 1 location
Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors
Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis
- 184 views
- 25 Mar, 2021
- 1 location
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naïve to TNF Inhibitors
Moderate to Severe Active Ulcerative Colitis Who Are Naïve to TNF Inhibitors
- 60 views
- 25 Mar, 2021
- 1 location
A Phase 2a, Randomized, Doubleblind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients with Diarrhea predominant Irritable Bowel Syndrome (IBS-D)
no history of inflammatory or immune-mediated GI disorders including, but not limited to, inflammatory bowel disease (Crohn’s disease, ulcerative colitis, microscopic colitis, and celiac disease
- 292 views
- 20 Aug, 2019
- 1 location
Are you at risk for C.diff? • Do you have an upcoming SURGERY, requiring you to be hospitalized for several days? • Have you been HOSPITALIZED TWICE in the last year and received antibiotics? • Are you 50 years of age or older?
Are you at risk for C.diff? • Do you have an upcoming SURGERY, requiring you to be hospitalized for several days? • Have you been HOSPITALIZED TWICE in the last year and received antibiotics? • Are you 50 years of age or older?
- 281 views
- 23 Nov, 2020
- 1 location
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy
- 816 views
- 08 Nov, 2020
- 1 location